NCT05208983

SafeTy and Efficacy of Preventative CoVID Vaccines

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 1,286 (actual)
• Sponsor: University Health Network, Toronto · Academic / Other
• Sex: All
• Age: 30 Years
• Healthy volunteers: Accepted

Summary

The STOPCoV study is a decentralized study comparing COVID-19 vaccine specific antibody levels at 24 weeks after final vaccine dose. We plan to study the safety and immunogenicity of COVID-19 vaccine(s) in community dwelling persons 70 years and over relative to a younger group (aged 30 - 50 years).

Detailed description

This is a prospective observational study of a cohort of individuals aged 30-50 years and a cohort of individuals aged 70 years and over receiving the COVID-19 vaccine. Participants will complete a questionnaire to determine eligibility. Eligible participants will complete and sign an e-consent and then be provided with a participant ID, log in information and password to the database portal, and then be enrolled into the study. Participants will complete the study assessments (baseline questionnaire, post vaccine symptom e-diary monthly, check-in questionnaire and dried blood spot specimens)

Conditions

• COVID-19 Virus Infection
• Vaccine Response

Interventions

Type	Name	Description
BIOLOGICAL	mRNA Vaccines or Viral vector-based vaccines for COVID	Participants receiving an approved COVID vaccine

Timeline

• Start date: 2021-05-06
• Primary completion: 2024-03-01
• Completion: 2024-04-01
• First posted: 2022-01-26
• Last updated: 2023-01-05

Locations

1 site across 1 country: Canada